Newsroom | 4882 results

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its new campaign, “The Day Diabetes Showed Up to Work,” in honor of Diabetes Awareness Month, which starts November 1. “Nearly 590 million people worldwide live with diabetes1, and approximately 70 percent are of working age. Yet too often their experience at work is shaped by misunderstanding, fear...

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. heeft vandaag bekendgemaakt dat het bedrijf een overeenkomst voor de aankoop van activa (APA) heeft gesloten met Biogen met betrekking tot twee oogheelkundige activa van Samsung Bioepis: BYOOVIZ ® (ranibizumab), een biosimilar die verwijst naar Lucentisi (ranibizumab) en OPUVIZ™ (aflibercept), een biosimilar die verwijst naar Eyleaii (aflibercept) — in Europa. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen...

INCHEON, Corée--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. a annoncé aujourd’hui avoir conclu un accord d’achat d’actifs (APA) avec Biogen concernant deux actifs ophtalmologiques de Samsung Bioepis : BYOOVIZ® (ranibizumab), un biosimilaire référencé Lucentisi (ranibizumab) et OPUVIZ™ (aflibercept), un biosimilaire référencé Eyleaii (aflibercept), en Europe. Samsung Bioepis assumera l’entière responsabilité de la commercialisation de BYOOVIZ dès le transfert des droits commerciaux de Biogen à Sa...

INCHEON, Corea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. oggi ha annunciato di aver sottoscritto un accordo di acquisto di asset (APA) da Biogen relativo a due asset oftalmici di Samsung Bioepis in Europa: BYOOVIZ® (ranibizumab), un biosimilare il cui prodotto di riferimento è Lucentisi (ranibizumab), e OPUVIZ™ (aflibercept), un biosimilare il cui prodotto di riferimento è Eyleaii (aflibercept). Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficial...

INCHEON, Corea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. ha anunciado hoy que la empresa ha firmado un acuerdo de compra de activos (APA) con Biogen para la comercialización de dos activos oftalmológicos de Samsung Bioepis: BYOOVIZ® (ranibizumab), un biosimilar homólogo de Lucentisi (ranibizumab), y OPUVIZ™ (aflibercept), un biosimilar homólogo de Eyleaii (aflibercept), en Europa. El comunicado en el idioma original es la versión oficial y autorizada del mismo. Esta traducción es solamente un...

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. gab heute bekannt, dass das Unternehmen mit Biogen einen Kaufvertrag (Asset Purchase Agreement, APA) über zwei Augenheilkunde-Produkte von Samsung Bioepis abgeschlossen hat: BYOOVIZ® (Ranibizumab), ein Biosimilar, das sich auf Lucentisi (Ranibizumab) bezieht, und OPUVIZ™ (Aflibercept), ein Biosimilar, das sich auf Eyleaii (Aflibercept) bezieht – in Europa. Samsung Bioepis wird nach der Übertragung der Vermarktungsrechte von Biogen zurüc...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced that the t:slim X2 insulin pump, featuring Control-IQ+ automated insulin delivery (AID) technology, is now available with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor integration in the United States.* This is the first step in a global commercial rollout that expands choice and personalization for people living with diabetes w...

PALO ALTO, Calif.--(BUSINESS WIRE)--Tidepool confirms co-founder Brandon Arbiter as CEO, marking its first leadership transition and continued momentum in diabetes innovation....

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. announced today that the company has entered into an Asset Purchase Agreement (APA) with Biogen regarding Samsung Bioepis’ two ophthalmology assets: BYOOVIZ® (ranibizumab), a biosimilar referencing Lucentisi (ranibizumab) and OPUVIZ™ (aflibercept), a biosimilar referencing Eyleaii (aflibercept) — in Europe. Samsung Bioepis will have full responsibility for commercialization of BYOOVIZ upon the transfer of commercial rights from Biogen b...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 24, 2025, the Company’s Board of Directors approved “inducement” grants to 84 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 127,230 restricted stock units. The grants are outside the Company’s stockholder-approved equity incentive plans and v...